Patents Assigned to Paratek Pharmaceuticals, Inc.
  • Patent number: 11129839
    Abstract: Methods of treating or preventing a bacterial infection in a subject are disclosed herein, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon. Also disclosed is a pharmaceutical composition comprising the compound of the present invention for treating or preventing a bacterial infection in a subject, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: September 28, 2021
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Michael P. Draper, S. Ken Tanaka
  • Publication number: 20210052609
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 25, 2021
    Applicants: Paratek Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
  • Patent number: 10835542
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: November 17, 2020
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
  • Patent number: 10383884
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 20, 2019
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
  • Patent number: 10238670
    Abstract: The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: March 26, 2019
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Amy L. Manley, Evangelos L. Tzanis, Lynne Garrity-Ryan, S. Ken Tanaka, Judith N. Steenbergen, Stephen Bai
  • Patent number: 10124014
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 13, 2018
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
  • Patent number: 10111890
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: October 30, 2018
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: S. Ken Tanaka, Evangelos L. Tzanis, Lynne Garrity-Ryan, Amy L. Manley
  • Publication number: 20180153908
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Application
    Filed: October 31, 2017
    Publication date: June 7, 2018
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern
  • Publication number: 20180078534
    Abstract: The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a citrate salt, and a phosphate salt. The present invention also provides methods for treating somnambulism. The methods include administering an emulsion that includes zolpidem, a bicarbonate salt, a metal oxide, and a borate salt.
    Type: Application
    Filed: March 30, 2017
    Publication date: March 22, 2018
    Applicant: PARATEK PHARMACEUTICALS, INC.
    Inventors: Nikhilesh N. Singh, Sathasivan I. Pather
  • Publication number: 20180055859
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
    Type: Application
    Filed: August 3, 2017
    Publication date: March 1, 2018
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: S. Ken Tanaka, Evangelos L. Tzanis, Lynne Garrity-Ryan, Amy L. Manley
  • Publication number: 20170333455
    Abstract: The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Application
    Filed: May 2, 2017
    Publication date: November 23, 2017
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Amy L. Manley, Evangelos L. Tzanis, Lynne Garrity-Ryan, S. Ken Tanaka
  • Patent number: 9724358
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: August 8, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
  • Publication number: 20170158616
    Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.
    Type: Application
    Filed: July 13, 2016
    Publication date: June 8, 2017
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Tadeusz Warchol
  • Publication number: 20170065517
    Abstract: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present inversion for treating sleep disorders such as insomnia are also provided.
    Type: Application
    Filed: March 10, 2016
    Publication date: March 9, 2017
    Applicant: PARATEK PHARMACEUTICALS, INC.
    Inventor: Nikhilesh N. SINGH
  • Patent number: 9562003
    Abstract: A method for modulating RNA with tetracycline compounds is described.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 7, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Stuart B. Levy, Michael P. Draper, Mark L. Nelson, Graham Jones
  • Patent number: 9533943
    Abstract: The present invention pertains, at least in part, to novel substituted etracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 3, 2017
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Todd Bowser, Mark Grier
  • Patent number: 9522872
    Abstract: Methods of synthesizing substituted tetracycline compounds are provided.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: December 20, 2016
    Assignee: PARATEK PHARMACEUTICALS, INC.
    Inventors: Farzaneh Seyedi, Tadeusz Warchol, Mark Grier
  • Patent number: 9481639
    Abstract: Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: November 1, 2016
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Haregewein Assefa, Beena Bhatia, Michael P. Draper, Laura Honeyman, Oak K. Kim, Dennis P. Molnar
  • Patent number: 9434680
    Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: September 6, 2016
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean Johnston, Tadeusz Warchol
  • Patent number: 9365500
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: June 14, 2016
    Assignee: PARATEK PHARMACEUTICALS, INC.
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia